Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

PET/MR Pre- og Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

30. september 2026 oppdatert av: University Health Network, Toronto

Undersøkende evaluering av samtidig hjerte-PET/MR, metabolomiske markører og sirkulerende DNA som mulige prognostiske markører for å identifisere pasienter som utvikler forbigående eller permanente kardiopulmonale dysfunksjoner etter strålebehandling

Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.

PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).

Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.

To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Detaljert beskrivelse

RT is a well-known and established therapy or adjuvant therapy for the treatment of thoracic malignancies (breast cancer, lung cancer, lymphoma and others). It usually uses high energy radiation from x-rays, gamma rays or other charged particles to induce DNA damage in malignant cells. Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, the signs and symptoms of radiation induced cardiopulmonary dysfunction (RICPD) still persist. However, in the majority of cases, it remains unclear which cardiopulmonary damage is the main /leading cause for the clinical symptoms the patients are experiencing.

Hybrid PET/MRI is a promising technique that allows for truly simultaneous molecular, anatomic and functional imaging of the cardiopulmonary system. The simultaneity is an important aspect in this proposed study since only parameters measured at the same time in PET and MR can be used for an integrated, multimodality parameter for possible detection and prognostication of the different underlying processes of cardiopulmonary dysfunction after RT. Furthermore, certain PET-uptake of the RV have to be corrected for RV mass which is only possible with concomitant anatomical imaging. MR imaging and PET at different time point are not accurately reflective of the underlying pathophysiological pathways and metabolic state at the specific time points pre- and post radiotherapy. To our knowledge, there are no online publications of its use in the diagnosis and prognostication of cardiopulmonary dysfunction after RT and specifically PH.

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • University Health Network
        • Ta kontakt med:
          • Patrick Veit-Haibach

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥18 years
  • Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy
  • Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.
  • A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age.
  • Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).

Exclusion Criteria:

  • Contraindication for MR as per current institutional guidelines.
  • Contraindication for Gadolinium injection as per current institutional guidelines.
  • Inability to lie supine for at least 45 minutes.
  • Any patient who is pregnant or breastfeeding.
  • Any patient with known hypersensitivity to 18F-FDG.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: One arm / exploratory study

Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours.

(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change of FDG uptake of heart
Tidsramme: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy

FDG uptake of the left and right ventricles of heart will be measured and compared in PETMRI scans

at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
Change of FDG uptake of lungs
Tidsramme: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy

FDG uptake of left and right ratios within the lungs in PETMRI scans

at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
Change of the heart function
Tidsramme: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy

MRI of ventricular volumes in PETMRI scans

at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
Change of the lung perfusion
Tidsramme: before radiotherapy and up to 16 weeks after completion of radiotherapy

Percentage of the perfused/ventilated lung segments will be evaluated and compared pre and post therapy by SPECT scans

before radiotherapy and up to 16 weeks after completion of radiotherapy

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Patrick Veit-Haibach, MD, University Health Network, Toronto

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juni 2021

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. september 2027

Datoer for studieregistrering

Først innsendt

17. mars 2021

Først innsendt som oppfylte QC-kriteriene

19. mai 2021

Først lagt ut (Faktiske)

26. mai 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere